Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

BUY
$26.24 - $39.63 $646,579 - $976,522
24,641 Added 1.89%
1,327,363 $52.2 Million
Q1 2023

May 15, 2023

BUY
$18.67 - $24.56 $726,636 - $955,875
38,920 Added 3.08%
1,302,722 $31.7 Million
Q4 2022

Feb 13, 2023

BUY
$17.24 - $23.95 $2.82 Million - $3.92 Million
163,795 Added 14.89%
1,263,802 $27.1 Million
Q3 2022

Nov 14, 2022

BUY
$9.4 - $18.59 $140,661 - $278,180
14,964 Added 1.38%
1,100,007 $19.7 Million
Q2 2022

Aug 12, 2022

BUY
$9.12 - $18.9 $272,925 - $565,601
29,926 Added 2.84%
1,085,043 $10.4 Million
Q1 2022

May 13, 2022

SELL
$12.15 - $16.83 $516,180 - $715,005
-42,484 Reduced 3.87%
1,055,117 $17.8 Million
Q4 2021

Feb 08, 2022

BUY
$13.83 - $18.78 $1.73 Million - $2.34 Million
124,791 Added 12.83%
1,097,601 $18.4 Million
Q3 2021

Nov 15, 2021

BUY
$7.07 - $17.5 $777,120 - $1.92 Million
109,918 Added 12.74%
972,810 $15.8 Million
Q2 2021

Aug 13, 2021

BUY
$5.69 - $7.17 $268,568 - $338,424
47,200 Added 5.79%
862,892 $5.45 Million
Q1 2021

May 12, 2021

SELL
$5.08 - $6.89 $258,145 - $350,122
-50,816 Reduced 5.86%
815,692 $5.04 Million
Q4 2020

Feb 11, 2021

SELL
$5.65 - $7.66 $11,390 - $15,442
-2,016 Reduced 0.23%
866,508 $5.99 Million
Q3 2020

Nov 16, 2020

BUY
$4.01 - $6.29 $1.45 Million - $2.28 Million
361,965 Added 71.46%
868,524 $4.9 Million
Q2 2020

Aug 14, 2020

BUY
$3.06 - $6.6 $1.33 Million - $2.87 Million
434,230 Added 600.35%
506,559 $2.58 Million
Q1 2020

May 14, 2020

BUY
$2.83 - $8.44 $21,171 - $63,139
7,481 Added 11.54%
72,329 $249,000
Q4 2019

Feb 14, 2020

SELL
$0.93 - $8.58 $20,628 - $190,312
-22,181 Reduced 25.49%
64,848 $556,000
Q2 2019

Aug 13, 2019

BUY
$1.21 - $1.48 $105,305 - $128,802
87,029 New
87,029 $114,000

Others Institutions Holding ISEE

About IVERIC bio, Inc.


  • Ticker ISEE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,078,000
  • Description
  • IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...
More about ISEE
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.